

Introduction & Notes re: RIVAP Annual Assessment Setting Workbook

Assessment Calculations for RIVAP's seventh full year of operations (12 months starting July 1, 2023)

Note: This KidsVax®'s final documentation for rates approved by the RI Department of Health in April, 2023

01. This workbook follows the naming conventions of having each tab or sheet begin with a letter (i.e., "a." through "d."), and each cell within each sheet be identified by row number (e.g., "01.") and column letter (e.g., "A"). So, to facilitate reference while collaborating via conference phone, users can refer to any single number, for example the new child vaccine calculated assessment rate, by a combination of the above. For that key number, the reference is "a.17.B".
02. The first assessment payment with the SFY24 rate will be due on July 31, 2023 for the assessment accounting months of Jul-Sep 2023 (i.e., the first quarter of the state fiscal year – SFY24). Assessments are due 30 days after the end of the quarter. Thus the assessment due on July 30, 2023 uses the measuring months of April - June 2023.
03. The primary spreadsheet for the work is the assessment calculation worksheet, worksheet a. The other sheets are intended to be reference or to develop background data in specific areas for the work. Key data for developing the primary funding target is on sheet b. which contains data supplied by the Rhode Island Department of Health (RIDOH) for the vaccine funding needs. Key numbers from a subsidiary sheet rolled into the main assessment sheet generally are shaded in yellow.
04. Key control points expected to be subject to policy decisions are coded in red font and shaded green. On the protected version of the sheets, cells not shaded green may be locked out to reduce the likelihood of user error. The password used is "RIVAP" -- this is not a matter of confidentiality, but rather to reduce error. Users who want to unlock the sheets for any reason are welcome to do so.
05. RIDOH reserves the right to adjust the assumptions which guide the assessment level. RIDOH may also determine to adjust the assessment setting process itself or this workbook structure at any time. It is anticipated going forward that new assessment rates will become effective on July 1 each year based upon calculations targeted to be completed in each immediately preceding April.

SIX MONTHS COVID DOSES

**Rhode Island Vaccine Assessment Program
Assessment Calculation Worksheet**

Column →	A	B	C	D	E	F	G
	CHILDREN			ADULTS			
Line ↓	Prior (2022/23)	SFY 2023/24		Prior (2022/23)	SFY 2023/24		Comments
A. Preliminary Vaccine Cost Estimates & Budget Parameters							
01.	\$17,116,830	\$23,034,859		\$19,534,091	\$33,133,086		Estimated vaccine costs
02.		\$0	0.0%	\$781,364	\$530,355	1.6%	Provision for vaccine cost increase
03.	\$2,038,967	\$1,822,982	8.3%	\$1,012,887	\$1,088,312	3.5%	Program operations costs (fluctuates based on program need)
04.	\$303,406	\$313,960		\$341,957	\$358,297		RI Vaccine Assessment Program (RIVAP) Funding operations
05.	\$1,561,638	\$2,576,424	10.0%	\$2,285,572	\$4,099,248	10.0%	State of RI Administrative Fee (DOA Cost Recovery)
06.	\$21,020,841	\$27,748,225		\$23,955,871	\$39,209,299		Net RIVAP Funds Needed by RIDOH
B. Assessable Covered Lives Estimates							
07.	88,104	86,479		536,264	547,601		Self-Reported Contribution Enrollees (sheet c.)
08.	0.00%	0	0.0%	0.00%	0	0.0%	Leakage (unknown insurer, out of reach entity, etc.)
09.	88,104	86,479		536,264	547,601		Assessable lives actually paying
C. Assessment Calculation							
10.	\$21,020,841	\$ 27,748,225		\$23,955,871	\$ 39,209,299		Costs to be raised
11.	\$608,386	\$504,381		\$141,509	\$ 105,440		TRICARE Revenue
12.	\$4,864,801	\$6,292,950	25.0%	\$5,417,575	\$8,777,513	25.0%	Working Capital Reserve (3 months of reserves)
13.	\$1,025,000	\$0		\$0	\$0		Additional COVID-19 Reserve
14.	-\$10,685,874	-\$7,772,554		-\$6,376,218	-\$6,888,886		RIVAP carryforward
15.	\$15,616,383	\$25,764,241		\$22,855,718	\$40,992,485		Total Assessment Billed
D. Per Assessable Covered Life Assessment							
16.	\$177.25	\$ 297.92		\$42.62	\$ 74.86		Annual Assessment per contribution enrollee
17.	\$14.78	\$ 24.83	68.0%	\$ 3.56	\$ 6.24	75.3%	Monthly Assessment per enrollee calculated/% Change
18.	\$14.78	\$ 24.83	68.0%	\$ 3.56	\$ 6.24	75.3%	Monthly Assessment per enrollee final/% Change
19.	\$19.88	\$26.74	34.5%	\$3.72	\$5.97	60.3%	Run Rate Monthly Assessment per enrollee /% change in RR
20.	\$20.88	\$28.08	13.1%	\$3.91	\$6.27	0.4%	Preliminary Assessment projection/Anticipated Increase
F. Overall Program Metrics							
21.	22.8%	20.5%		17.9%	16.5%		Total non-vaccine costs as % of RIDOH vaccine costs
22.	39.7%	28.0%		28.7%	25.4%		Private purchase costs above RIDOH vaccine costs

Notes:

- RIDOH costs raised via assessments pursuant to statutory authorization. (Capped at 15% -- budget is set by RIDOH outside of this program.)
- KidsVax comprehensive administrative services, executive director and technology fee.
- % of Revenues Raised as set by the Rhode Island Department of Administration.
- The CDC contract prices change dates are 4/1 for childhood vaccines and 7/1 for adult vaccines. The child price increase is 0 on Line 2 because RIDOH anticipates purchasing vaccines administered in April-June 2024 in March 2024, at April 2023 prices. All childhood vaccine cost projections are based on April 2023 CDC pricing. The line 2 provision for cost increases is applied for 12 months for adult vaccines in order to estimate July 2023 CDC prices.
- Carryforward cash amounts, if any, will be applied to reduce subsequent years' assessments (see line 13).
- Preliminary projection: This is the normalized assessment rate and one additional year of inflation.
- TRICARE is not in compliance with RIDOH's assessment system. Its non-compliance is in dispute. The amount shown is a good faith estimate of the minimum TRICARE is expected to pay in SFY 2023/2024 based upon its payments in 2022/2023.

SIX MONTHS COVID DOSES

SFY2024 Vaccine Budget		Vaccine Information					Current PO Values				
Tab	Vaccine	NDC	CDC Contract	Doses per unit	Units per box	FET Anti-gens	Dose Qty	Cost p/dose	FET p/dose	Ext. Cost p/dose	PO Value
30	DT	49281-0225-10	Sole Source	1	10	2	0	\$ (1,500)	\$ 1.50	\$ -	\$ -
3	IPOL (EIPV)	49281-0860-10	2-2022-13471	10	1	1	1,400	\$ 15.230	\$ 0.75	\$ 15.980	\$ 22,372
5	MenQuadfi MCV4	49281-0590-05	2-2022-13471	1	5	1	13,500	\$ 107.088	\$ 0.75	\$ 107.838	\$ 1,455,813
6	TD	13533-0131-01	2-2022-13470	1	10	2	650	\$ 17.009	\$ 1.50	\$ 18.509	\$ 12,031
10	Pprevnar 13 (PCV 13)	00005-1971-02	2-2022-13473	1	10	1	10,750	\$ 161.520	\$ 0.75	\$ 162.270	\$ 1,744,403
8	Bexsero	58160-0976-20	2-2022-13474	1	10	1	8,800	\$ 140.959	\$ 0.75	\$ 141.709	\$ 1,247,039
11	Infanrix (DTaP)	58160-0810-52	2-2022-13474	1	10	3	6,000	\$ 18.843	\$ 2.25	\$ 21.093	\$ 126,558
12	Vaxelis	63361-0243-15	2-2022-13472	1	10	5	15,800	\$ 94.040	\$ 3.75	\$ 97.790	\$ 1,545,082
13	Kinrix (DTaP/IPV)	58160-0812-52	2-2022-13474	1	10	4	6,100	\$ 43.960	\$ 3.00	\$ 46.960	\$ 286,456
14	Havrix (Hep A)	58160-0825-52	2-2022-13474	1	10	1	17,000	\$ 22.251	\$ 0.75	\$ 23.001	\$ 391,017
15	Engerix-B (Hep B)	58160-0820-52	2-2022-13474	1	10	1	6,850	\$ 16.140	\$ 0.75	\$ 16.890	\$ 115,697
18	Rotarix (Rota)	58160-0854-52	2-2022-13474	1	10	1	10,900	\$ 104.704	\$ 0.75	\$ 105.454	\$ 1,149,449
19	Boostrix (TDaP)	58160-0842-52	2-2022-13474	1	10	3	8,000	\$ 33.755	\$ 2.25	\$ 36.005	\$ 288,040
22	PedvaxHib (Hib)	00006-4897-00	2-2022-13472	1	10	1	8,200	\$ 14.914	\$ 0.75	\$ 15.664	\$ 128,445
9	Gardasil (HPV9)	00006-4121-02	2-2022-13472	1	10	1	20,000	\$ 223.880	\$ 0.75	\$ 224.630	\$ 4,492,600
24	MMR II	00006-4681-00	2-2022-13472	1	10	3	6,750	\$ 22.705	\$ 2.25	\$ 24.955	\$ 168,446
25	Proquad MMRV	00006-4171-00	2-2022-13472	1	10	4	8,850	\$ 162.094	\$ 3.00	\$ 165.094	\$ 1,461,082
26	Pneumovax23 (Pedi)	00006-4837-03	2-2022-13472	1	10	0	400	\$ 65.800	\$ -	\$ 65.800	\$ 26,320
28	Varivax	00006-4827-00	2-2022-13472	1	10	1	9,100	\$ 131.670	\$ 0.75	\$ 132.420	\$ 1,205,022
23	Menveo	58160-0955-09	2-2022-13474	1	5	1	200	\$ 104.850	\$ 0.75	\$ 105.600	\$ 21,120
	Pprevnar 20	00005-2000-10	2-2022-14073	1	10	1	10,750	\$ 172.246	\$ 0.75	\$ 172.996	\$ 1,859,707
	RSV						5,051	\$ 300.000	\$ -	\$ 300.000	\$ 1,515,150
Influenza	Fluarix 0.5ml (6 months -18 yrs)	58160-0890-52	CDC	1	10	1	25,850	\$ 14.466	\$ 0.75	\$ 15.22	\$ 393,334
	Flulaval 0.5ml (6 mos - 18 yrs)	19515-0808-52	CDC	1	10	1	25,850	\$ 14.466	\$ 0.75	\$ 15.22	\$ 393,334
	Flumist (2-18 yrs)	66019-0309-10	CDC	1	10	1	3,520	\$ 18.760	\$ 0.75	\$ 19.51	\$ 68,675
	Flucelvax (6 months - 18 yrs)	70461-0322-03	CDC	0	0	0	4,700	\$ 20.320	\$ 0.75	\$ 21.07	\$ 99,029
COVID	COVID-19 Vaccine (<19 years)						25,624	\$ 110.000	\$ -	\$ 110.00	\$ 2,818,640
Total Pediatric							260,595	<= Doses	Cost =>		\$23,034,859
29	Pneumovax23 (PPV23 - Ad)	N/A	N/A	1	10	0	0	\$ -	\$ -	\$ -	\$ -
32	Gardisal (HPV9 - Ad)	00006-4121-02	2-2022-14072	1	10	1	4,800	\$ 163.810	\$ 0.75	\$ 164.56	\$ 789,888
20	MMR II (MMR - Ad)	00006-4681-00	2-2022-14072	1	10	3	6,000	\$ 53.640	\$ 2.25	\$ 55.89	\$ 335,340
21	Varivax (Var - Ad)	00006-4827-00	2-2022-14072	1	10	1	2,300	\$ 95.900	\$ 0.75	\$ 96.65	\$ 222,295
16	Bexsero (MenB)	58160-0976-20	2-2022-14070	1	10	1	3,000	\$ 117.617	\$ 0.75	\$ 118.37	\$ 355,101
31	Twinrix (Hep AB)	58160-0815-52	2-2022-14070	1	10	2	600	\$ 66.423	\$ 1.50	\$ 67.92	\$ 40,754
17	Pprevnar 20	00005-2000-10	2-2022-14073	1	10	1	35,000	\$ 172.246	\$ 0.75	\$ 173.00	\$ 6,054,860
27	(Td - Ad)	13533-0131-01	2-2022-14071	1	10	2	7,500	\$ 15.778	\$ 1.50	\$ 17.28	\$ 129,585
7	Adacel (Tdap - Ad)	49281-0400-20	2-2022-14074	1	5	3	58,000	\$ 25.976	\$ 2.25	\$ 28.23	\$ 1,637,108
1	MenQuadfi (MCV4 - Ad)	49281-0590-05	2-2022-14074	1	5	1	2,700	\$ 79.486	\$ 0.75	\$ 80.24	\$ 216,637
2	Heplisav-B (Hep B-Ad)	43528-0003-05	2-2022-14069	1	5	1	8,700	\$ 74.190	\$ 0.75	\$ 74.94	\$ 651,978
4	Havrix (Hep A)	58160-0826-52	2-2022-14070	1	10	1	4,500	\$ 37.819	\$ 0.75	\$ 38.57	\$ 173,561
Influenza	Fluzone PF 0.5ml (19+ yrs)	49281-0422-50	CDC	1	10	1	100,000	\$ 14.156	\$ 0.75	\$ 14.91	\$ 1,490,600
	Flucelvax 0.5ml (19+ yrs)	70461-0322-03	CDC	1	10	1	62,660	\$ 18.280	\$ 0.75	\$ 19.03	\$ 1,192,420
	Fluzone HD	0	MMCAP	1	10	1	55,000	\$ 61.520	\$ 0.75	\$ 62.27	\$ 3,424,850
	Fluad (65+ yrs)	0	MMCAP	1	10	1	50,000	\$ 59.870	\$ 0.75	\$ 60.62	\$ 3,031,000
COVID	COVID-19 Vaccine (19+years)						121,701	\$ 110.000	\$ -	\$ 110.000	\$ 13,387,110
Total Adult							522,461	<= Doses	Cost =>		\$33,133,086.30

Pediatric Vaccine Projection Summary

SFY 2023/24

	Cost Per Dose	Doses	Total Cost
Prior Year Projected	\$75.18	227,670	\$17,116,830
Fiscal Year Projected	\$88.39	260,595	\$23,034,859
Variance	\$13.21	32,925	\$5,918,029
% Variance	17.6%	14.5%	34.6%

Projection Change Drivers:

The 12.7% cost per dose increase is due to the addition of RSV and COVID vaccines.

Holding the vaccine mix constant, the increase per dose is 5%. This is a little high relative to the more typical 3-4% CDC price increase.

The increase in the number of doses is mainly due to the addition of RSV and COVID vaccines.

Adult Vaccine Projection Summary

SFY 2023/24

	Cost Per Dose	Doses	Total Cost
Prior Year Projected	\$41.17	474,490	\$19,534,091
Fiscal Year Projected	\$63.42	522,461	\$33,133,086
Variance	\$22.25	47,971	\$13,598,995
% Variance	54.0%	10.1%	69.6%

Projection Change Drivers:

The 54.0% cost per dose increase, is due to the addition of the COVID vaccine, as well as fewer doses for lower cost flu vaccines and increased doses for the more costly

Excluding the removal of Pneumovax23 and holding the vaccine mix constant, the increase per dose is 4%. This is in line with the typical 3-4% CDC price increase.

The increase in the number of doses is mainly due to the addition of the COVID vaccine, partially offset by reduced flu doses and the removal of Pneumovax23.

SIX MONTHS COVID DOSES

**Rhode Island Vaccine Assessment Program
Estimated Contribution Enrollees For SFY 2024 Assessment Calculation**

Contribution Enrollees reported to KV by quarter:

Column → Line ↓	A	B	C	D	E	F	G	H	I
	Assessment Quarter	Membership Period	Quarter Kids	Adults	Kids	Monthly Average Adults	Total	Monthly Average (using 12 months) Kids	Adults
01.	FY 21 Q4	1/2021-3/2021	266,783	1,595,943	88,928	531,981	620,909	89,722	528,195
02.	FY 22 Q1	4/2021-6/2021	263,657	1,597,397	87,886	532,466	620,351	88,852	530,353
03.	FY 22 Q2	7/2021-9/2021	263,830	1,616,558	87,943	538,853	626,796	88,343	533,202
04.	FY 22 Q3	10/2021-12/2021	262,982	1,625,271	87,661	541,757	629,418	88,104	536,264
05.	FY 22 Q4	1/2022-3/2022	261,012	1,631,398	87,004	543,799	630,803	87,623	539,219
06.	FY 23 Q1	4/2022-6/2022	259,233	1,638,766	86,411	546,255	632,666	87,255	542,666
07.	FY 23 Q2	7/2022-9/2022	258,413	1,647,589	86,138	549,196	635,334	86,803	545,252
08.	FY 23 Q3	10/2022-12/2022	259,091	1,653,456	86,364	551,152	637,516	86,479	547,601
05.	Most Recent Year Average				86,479	547,601			
06.	Most Recent Year Max				87,004	551,152		<u>Variance</u>	
								<u>Kids</u>	<u>Adults</u>
07.	Most Recent year Min				86,138	543,799		1.0%	1.4%